目的 基于网络药理学方法探讨麻杏石甘汤的主要活性成分及治疗支气管哮喘的作用机制。方法 在中药系统药理学分析平台（TCMSP）数据库中检索麻杏石甘汤的化学成分及靶点，采用Cytoscape 3.7.2软件构建活性成分-预测靶点网络图。在Genecards数据库中获取支气管哮喘疾病靶点，与药物靶点映射获得麻杏石甘汤作用于支气管哮喘的预测靶点。通过STRING数据库构建靶点相互作用网络，导入Cytoscape 3.7.2中筛选麻杏石甘汤的核心靶点。利用DAVID数据库及Cytoscape3.7.2对麻杏石甘汤的核心靶点进行KEGG信号通路和GO生物过程富集分析，并构建麻杏石甘汤活性成分-核心靶点-信号通路网络图。结果 预测结果显示，麻杏石甘汤中136个主成分可靶向98个哮喘相关靶点，关键有效成分包括麻黄碱、槲皮素、木犀草素、山柰酚等，核心靶点包括IL-6、MAPK3、TNF、TP53、VEGFA、JUN、EGFR、EGF、NOS3、CAT，涉及HIF-1、PI3K-Akt、MAPK、雌激素等71个信号通路和RNA聚合酶II启动子转录、细胞凋亡过程、ERK1和ERK2级联的正调控、上皮细胞增殖、平滑肌细胞增殖等20个生物过程。结论 初步揭示了麻杏石甘汤的药效物质基础及治疗支气管哮喘的机制，为麻杏石甘汤治疗支气管哮喘的研究提供参考。

Objective To explore the active components and mechanism of Maxing Shigan Decoction in the treatment of bronchial asthma by network pharmacology. Methods Firstly, the components of Maxing Shigan decoction were searched through the Chinese Medicine System Pharmacology (TCMSP) database. Cytoscape 3.7.2 was used to build a network between components and targets. Bronchial asthma disease targets were obtained in Genecards database, then mapped with drug targets to obtain the predicted targets of Maxing Shigan Decoction for bronchial asthma. The target interaction network was constructed through the STRING database and imported into Cytoscape 3.7.2 to screen the core targets of Maxing Shigan Decoction. Finally, DAVID database and Cytoscape 3.7.2 were used to perform KEGG pathway enrichment analysis and GO biological process enrichment analysis, and build active ingredients-key targets-KEGG pathway network map. Results Network pharmacological analysis shows that 136 main components in MaXing Shigan Decoction correspond to 98 asthma targets. The key active ingredients include ephedrine, quercetin, luteolin, kaempferol, etc. The core targets include:IL-6, MAPK3, TNF, TP53, VEGFA, JUN, EGFR, EGF, NOS3, CAT. KEGG signaling pathway analysis obtained 68 signaling pathways, mainly related to:HIF-1、PI3K-Akt、MAPK and Estrogen signaling pathway, etc. GO biological process analysis obtained 20 biological processes, mainly involved in positive regulation of transcription from RNA polymerase II promoter, Apoptotic process, positive regulation of ERK1 and ERK2 cascade, Epithelial cell proliferation and smooth muscle cell proliferation, etc. Conclusion This study preliminarily revealed the pharmacodynamic substance basis of Maxing Shigan Decoction and its possible mechanisms for treating bronchial asthma, providing reference for the study of Maxing Shigan decoction in the treatment of bronchial asthma.

R285.5

河南省自然科学基金资助项目（182300410310）